Rebalancing Your Geographic Footprint for Innovation in Clinical Research

Session details:

• How do we focus our attention on where we need to be? Balancing regulatory requirements with where you can readily execute trials

• Most Favored Nation Directive’s impact on footprint, timelines, and global allocation

• Assessment of emerging geographies, China, Australia, India, Saudi Arabia, UAE and Africa
• Innovation coming out of China & Australia, speed of phase I trials and how that feeds into proof of concept and regulatory strategies